Delcath Systems Announces a KOL Call on November 5, 2020 to discuss the Results of a Prospective Phase II Study in Patients with Metastatic Ocular Melanoma
29. Oktober 2020 07:30 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today...
Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive Officer
01. Oktober 2020 16:07 ET
|
Delcath Systems, Inc.
Gerard Michel Brings the Experience Needed to Lead Delcath as it Transitions from a Development to Commercial Stage CompanyJohn Purpura Appointed Chief Operating Officer with Operational,...
Delcath Systems, Inc. to Participate in Upcoming Virtual Investor Conferences
10. September 2020 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers,...
Delcath to Present at the LD Micro 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 3:00pm ET
25. August 2020 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today...
Delcath Systems, Inc. Announces Second Quarter 2020 Results
13. August 2020 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results
06. August 2020 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today...
Delcath to Present at Canaccord Genuity 40th Annual Growth Conference
03. August 2020 13:48 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today...
Delcath Announces Leadership Transition
26. Mai 2020 08:30 ET
|
Delcath Systems, Inc.
Appoints John Purpura as interim Chief Executive Officer.Reiterates intention to announce top-line data from Phase 3 FOCUS trial by year-endAccelerates shift to commercialization planning NEW YORK,...
Delcath Announces First Quarter 2020 Results
15. Mai 2020 06:30 ET
|
Delcath Systems, Inc.
Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020 NEW YORK, May 15, 2020 ...
Delcath Systems Closes $22.0 Million Public Offering of Common Stock
05. Mai 2020 16:05 ET
|
Delcath Systems, Inc.
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...